Logo
x

Search

Subscribe Now

Biocytogen

Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases

Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases

  • February 21, 2024
Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement

Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement

  • December 20, 2023
Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer

Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer

  • July 6, 2023
Biocytogen’s Subsidiary Eucure Biopharma Signs an Exclusive License Agreement with Chipscreen’s Holding Subsidiary Chipscreen NewWay for YH008

Biocytogen’s Subsidiary Eucure Biopharma Signs an Exclusive License Agreement with Chipscreen’s Holding Subsidiary Chipscreen NewW...

  • February 28, 2023
Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies

Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies

  • November 29, 2022
Biocytogen Entered into an Agreement with CtM Biotech to Co-develop TCR-Mimic Antibody-Based Multi-Specific T Cell Engagers for Cancer

Biocytogen Entered into an Agreement with CtM Biotech to Co-develop TCR-Mimic Antibody-Based Multi-Specific T Cell Engagers for Ca...

  • April 19, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.